These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37601796)

  • 1. Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing
    Merad Y; Conrad A; Brosset S; Schmidt A; Hanriat C; Lustig S; Laurent F; Kolenda C; Roussel-Gaillard T; Batailler C; Ferry T;
    Front Med (Lausanne); 2023; 10():1224922. PubMed ID: 37601796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.
    Mauri C; Maraolo AE; Di Bella S; Luzzaro F; Principe L
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
    Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria.
    Simon M; Gerlach RG; Pfeifer Y; Pfennigwerth N; Gatermann SG; Schröder A; Hiergeist A; Hamprecht A; Rügamer T; Gessner A; Jantsch J
    Front Microbiol; 2022; 13():977330. PubMed ID: 36483203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
    Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam.
    Rubnitz ZA; Kunkel VN; Baselski VS; Summers NA
    Cureus; 2022 Sep; 14(9):e28855. PubMed ID: 36225496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
    Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
    Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
    Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.
    Biagi M; Wu T; Lee M; Patel S; Butler D; Wenzler E
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31570403
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.
    Sreenivasan P; Sharma B; Kaur S; Rana S; Biswal M; Ray P; Angrup A
    J Antibiot (Tokyo); 2022 Aug; 75(8):454-462. PubMed ID: 35715617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.
    Tan X; Kim HS; Baugh K; Huang Y; Kadiyala N; Wences M; Singh N; Wenzler E; Bulman ZP
    Infect Drug Resist; 2021; 14():125-142. PubMed ID: 33500635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
    Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
    Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
    Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in
    Ma K; Zong Z
    Front Microbiol; 2022; 13():1047109. PubMed ID: 36406430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
    Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.